
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
Details : Infigratinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Achondroplasia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 11, 2025
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Interventional Study of Infigratinib in Children With Hypochondroplasia
Details : Infigratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hypochondroplasia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2025
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Infigratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Achondroplasia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2023
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : LianBio
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Truseltiq (infigratinib) is an oral small molecule, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven gastric cancer or gastroesophageal junction adenocarcinoma and to target achondroplasia at its source.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2023
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : LianBio
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
Details : Infigratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Achondroplasia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 06, 2021
Lead Product(s) : Infigratinib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Guru P. Sonpavde
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Infigratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Transitional Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 22, 2021
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Guru P. Sonpavde
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : BridgeBio Pharma
Deal Size : $2,000.0 million
Deal Type : Collaboration
Details : BridgeBio will retain all rights to infigratinib in skeletal dysplasia, including achondroplasia. Subject to U.S. FDA approval, QED and Helsinn will co-commercialize infigratinib in oncology indications in the U.S. and will share profits and losses on a ...
Product Name : Truseltiq
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 31, 2021
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : BridgeBio Pharma
Deal Size : $2,000.0 million
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : BridgeBio Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The U.S. FDA has accepted New Drug Application (NDA) for infigratinib, an oral FGFR1-3 selective inhibitor, for individuals with cholangiocarcinoma, or cancer of the bile ducts. Application accepted under Priority Review designation.
Product Name : Truseltiq
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 01, 2020
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : BridgeBio Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Jennifer Lee Caswell-Jin
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Infigratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 07, 2020
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Jennifer Lee Caswell-Jin
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data will be presented reports consistent treatment response in both first-line and later-line treatment settings after Infigratinib (BGJ398) treatment in advanced/unresectable or metastatic urothelial carcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 29, 2020
Lead Product(s) : Infigratinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
